HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Olezarsen cut triglycerides 64% but did not change plaque in ESSENCE-TIMI 73b imaging

Louis Nervegna · Mar 31, 2026 · ♥ 6 reactions · 0 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugs
AI summary & key facts

The ESSENCE-TIMI 73b imaging study found olezarsen lowered triglycerides about 64% and remnant cholesterol about 72%, with ApoB down only about 16%, yet 12-month CCTA showed no difference in plaque. Louis reads it as showing TG lowering alone, without treating insulin resistance, does not slow plaque.

This trial shows very clearly that lowering high triglycerides— without treating the underlying insulin resistance that causes it— does not slow plaque growth.

#triglyceridesHD #vldlHD #apobHD #remnantsHD #insulinresistanceHD

Research cited

🧬🫀 Massive triglyceride reduction… zero plaque impact?

Very interesting study but IMHO with methodological flaws affecting the results.

The Essence–TIMI 73b imaging study tested a bold hypothesis:
👉 If you dramatically reduce triglyceride-rich lipoproteins,
👉 you should slow atherosclerosis.

Enter olezarsen (APOC3 inhibition).

🔬 What did they achieve?

Impressive biology:
🔻 Triglycerides ↓ ~64%
🔻 Remnant cholesterol ↓ ~72%
🔻 ApoB ↓ ~16%
➖ LDL-C unchanged

And yet…

📊 What happened to coronary plaque?

Measured by CCTA over 12 months:
👉 No difference vs placebo in:
✔️ Non-calcified plaque volume
✔️ Low-attenuation plaque
✔️ Total plaque burden

📉 Primary endpoint: neutral (p=0.36)

⚠️ So what’s going on?

This is the key message:
👉 Not all lipid lowering is equal.

Despite massive triglyceride reduction:
✔️ ApoB reduction was modest (~16%)
✔️ Patients were already aggressively treated (97% on therapy)
✔️ Follow-up may be too short for structural change

💡 The uncomfortable implication

We’ve been told:
“Triglyceride-rich lipoproteins are highly atherogenic.”

But this study challenges the clinical translation of that concept.

👉 Lowering TRLs ≠ necessarily shrinking plaque (at least short-term)

🎯 Clinical perspective
This is not a negative study.

It’s a clarifying one:
✔ Biology ≠ imaging effect
✔ Surrogate ≠ disease modification
✔ Mechanism matters

🔮 Bottom line

If you want to move plaque, you still need to move:
👉 atherogenic particle burden (apoB)

Everything else may be… secondary.

And maybe it’s time to stop asking:
“Did we lower triglycerides?”
…and start asking:
👉 “Did we actually change the disease?”

No photo description available.
← newer: Analysis of 125 million statin users links statins to lower older: EZ-PAVE: LDL target <55 vs <70 cut major CV events by 33% in →